DeepMed Research

MERCK KGAA

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1668-01-01

Employees: 62.9K

Market Cap: $84.2B

Website: http://www.merckgroup.com/de

Clinical Trials

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Phase 1

Completed

Conditions: Non-small Cell Lung Cancer

Interventions: Drug: Tepotinib
Drug: Pemetrexed
Drug: Gefitinib
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2013-11-13

Last Posted Date: 2022-11-08

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 88

Registration Number: NCT01982955

Locations: 🇨🇳
Jilin University, Changchun, China
🇨🇳
Jilin Cancer Hospital, Changchun, China
🇨🇳
Guangdong Provincial People's Hospital, Guangzhou, China

and more 41 locations

Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension

Phase 3

Completed

Conditions: Hypertension

Interventions: Drug: Bisoprolol/Amlodipine (Bisoprolol failed group)
Drug: Bisoprolol/Amlodipine (Amlodipine failed group)

First Posted Date: 2013-11-07

Last Posted Date: 2017-01-30

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 200

Registration Number: NCT01977794

Locations: 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany

ATX-MS-1467 in Multiple Sclerosis

Phase 2

Completed

Conditions: Multiple Sclerosis

Interventions: Drug: ATX-MS-1467

First Posted Date: 2013-10-31

Last Posted Date: 2017-07-02

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 37

Registration Number: NCT01973491

Locations: 🇩🇪
Please contact the Merck KGaA Communication Center, Darmstadt, Germany

Japanese Phase 1 Trial of Sym004 in Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Sym004

First Posted Date: 2013-10-07

Last Posted Date: 2017-08-23

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 51

Registration Number: NCT01955473

Locations: 🇩🇪
Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany

Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Avelumab 10 mg/kg
Drug: Avelumab 20 mg/kg
Drug: Avelumab 3 mg/kg

First Posted Date: 2013-09-17

Last Posted Date: 2020-09-30

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 57

Registration Number: NCT01943461

Locations: 🇩🇪
Research site, Darmstadt, Germany

Study to Verify Clinical Utility of Point-of-Care (POC) Thyroid Stimulating Hormone (TSH) Test Kits as Compared to Third Generation TSH Test Kit

Phase 4

Completed

Conditions: Hypothyroidism

Interventions: Device: Quantitative POC TSH Kit
Device: Qualitative POC TSH Kit
Device: Third generation TSH Kit

First Posted Date: 2013-08-13

Last Posted Date: 2014-11-25

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 283

Registration Number: NCT01921452

Locations: 🇨🇳
Research site, Shanghai, China

Low-dose Gonal-f® in Ovulation Induction

Phase 4

Terminated

Conditions: Infertility
Monofollicular Development

Interventions: Drug: Gonal-f®

First Posted Date: 2013-06-06

Last Posted Date: 2016-08-11

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 24

Registration Number: NCT01871532

Locations: 🇬🇧
Research Site, Nottingham, United Kingdom
🇬🇧
Research site, London, United Kingdom

Phase 3 Trial to Evaluate the Efficacy and Safety of COL-1620 Vaginal Progesterone Gel

Phase 3

Completed

Conditions: Luteal Hormone Supplementation in In-vitro Fertilization
Embryo Transfer

Interventions: Drug: COL-1620
Drug: Gonadotropin-releasing hormone (GnRH) analogue
Drug: Follicle-stimulating hormone (FSH)
Drug: Human Chorionic Gonadotropin (hCG)

First Posted Date: 2013-05-29

Last Posted Date: 2015-12-21

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 178

Registration Number: NCT01863680

Locations: 🇯🇵
Research site, Yokohama, Kanagawa, Japan

A Japanese Phase 1 Trial of TH-302 in Subjects With Solid Tumors and Pancreatic Cancer

Phase 1

Completed

Conditions: Solid Tumor
Pancreatic Cancer

Interventions: Drug: Evofosfamide
Drug: Gemcitabine

First Posted Date: 2013-04-17

Last Posted Date: 2018-10-15

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 20

Registration Number: NCT01833546

Locations: 🇯🇵
Research Site, Tokyo, Japan

A Japanese Phase 1 Trial of c-Met Inhibitor MSC2156119J in Subjects With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: MSC2156119J

First Posted Date: 2013-04-16

Last Posted Date: 2020-08-06

Lead Sponsor: Merck KGaA, Darmstadt, Germany

Target Recruit Count: 12

Registration Number: NCT01832506

Locations: 🇯🇵
Research site, Shizuoka, Japan

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy